- Home
- NRXP vs SCYX Comparison
NRXP vs SCYX Comparison
Compare NRXP & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- SCYX
- Stock Information
- Founded
- NRXP 2015
- SCYX 1999
- Country
- NRXP United States
- SCYX United States
- Employees
- NRXP N/A
- SCYX N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- NRXP Health Care
- SCYX Health Care
- Exchange
- NRXP Nasdaq
- SCYX Nasdaq
- Market Cap
- NRXP 34.7M
- SCYX 40.9M
- IPO Year
- NRXP N/A
- SCYX 2014
- Fundamental
- Price
- NRXP $2.01
- SCYX $0.95
- Analyst Decision
- NRXP Strong Buy
- SCYX Buy
- Analyst Count
- NRXP 4
- SCYX 1
- Target Price
- NRXP $28.25
- SCYX N/A
- AVG Volume (30 Days)
- NRXP 185.3K
- SCYX 115.0K
- Earning Date
- NRXP 05-13-2025
- SCYX 03-12-2025
- Dividend Yield
- NRXP N/A
- SCYX N/A
- EPS Growth
- NRXP N/A
- SCYX N/A
- EPS
- NRXP N/A
- SCYX N/A
- Revenue
- NRXP N/A
- SCYX $3,746,000.00
- Revenue This Year
- NRXP N/A
- SCYX $1,541.00
- Revenue Next Year
- NRXP N/A
- SCYX $111.43
- P/E Ratio
- NRXP N/A
- SCYX N/A
- Revenue Growth
- NRXP N/A
- SCYX N/A
- 52 Week Low
- NRXP $1.10
- SCYX $0.82
- 52 Week High
- NRXP $6.01
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- NRXP 42.26
- SCYX 42.75
- Support Level
- NRXP $1.95
- SCYX $0.94
- Resistance Level
- NRXP $2.12
- SCYX $1.06
- Average True Range (ATR)
- NRXP 0.18
- SCYX 0.06
- MACD
- NRXP 0.01
- SCYX -0.00
- Stochastic Oscillator
- NRXP 23.08
- SCYX 38.46
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.